{"id":33508,"date":"2025-05-15T14:51:42","date_gmt":"2025-05-15T06:51:42","guid":{"rendered":"https:\/\/flcube.com\/?p=33508"},"modified":"2025-05-15T14:51:43","modified_gmt":"2025-05-15T06:51:43","slug":"boehringer-ingelheims-nerandomilast-filing-accepted-for-review-in-progressive-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33508","title":{"rendered":"Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis"},"content":{"rendered":"\n

Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the filing for another indication approval of its investigational drug nerandomilast for the treatment of progressive pulmonary fibrosis (PPF). The preferential inhibitor of phosphodiesterase 4B (PDE4B) is also awaiting regulatory decisions from the NMPA for the treatment of idiopathic pulmonary fibrosis (IPF).<\/p>\n\n\n\n

Phase III Study Results<\/strong>
The summary results of the pivotal Phase III FIBRONEER-ILD study demonstrated promising outcomes. At week 52 of treatment with nerandomilast, the absolute change in forced vital capacity (FVC, mL) from baseline reached the primary endpoint compared to placebo. This indicates the potential of nerandomilast to address the unmet medical needs in patients with progressive pulmonary fibrosis.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products…<\/p>\n","protected":false},"author":1,"featured_media":33509,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[390,38],"class_list":["post-33508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boehringer-ingelheim","tag-market-approval-filings"],"yoast_head":"\nBoehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the filing for another indication approval of its investigational drug nerandomilast for the treatment of progressive pulmonary fibrosis (PPF). The preferential inhibitor of phosphodiesterase 4B (PDE4B) is also awaiting regulatory decisions from the NMPA for the treatment of idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33508\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the filing for another indication approval of its investigational drug nerandomilast for the treatment of progressive pulmonary fibrosis (PPF). The preferential inhibitor of phosphodiesterase 4B (PDE4B) is also awaiting regulatory decisions from the NMPA for the treatment of idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33508\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-15T06:51:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T06:51:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis\",\"datePublished\":\"2025-05-15T06:51:42+00:00\",\"dateModified\":\"2025-05-15T06:51:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508\"},\"wordCount\":138,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1510.webp\",\"keywords\":[\"Boehringer Ingelheim\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33508#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33508\",\"name\":\"Boehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1510.webp\",\"datePublished\":\"2025-05-15T06:51:42+00:00\",\"dateModified\":\"2025-05-15T06:51:43+00:00\",\"description\":\"Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the filing for another indication approval of its investigational drug nerandomilast for the treatment of progressive pulmonary fibrosis (PPF). The preferential inhibitor of phosphodiesterase 4B (PDE4B) is also awaiting regulatory decisions from the NMPA for the treatment of idiopathic pulmonary fibrosis (IPF).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33508\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1510.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33508#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis - Insight, China's Pharmaceutical Industry","description":"Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the filing for another indication approval of its investigational drug nerandomilast for the treatment of progressive pulmonary fibrosis (PPF). The preferential inhibitor of phosphodiesterase 4B (PDE4B) is also awaiting regulatory decisions from the NMPA for the treatment of idiopathic pulmonary fibrosis (IPF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33508","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis","og_description":"Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the filing for another indication approval of its investigational drug nerandomilast for the treatment of progressive pulmonary fibrosis (PPF). The preferential inhibitor of phosphodiesterase 4B (PDE4B) is also awaiting regulatory decisions from the NMPA for the treatment of idiopathic pulmonary fibrosis (IPF).","og_url":"https:\/\/flcube.com\/?p=33508","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-15T06:51:42+00:00","article_modified_time":"2025-05-15T06:51:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33508#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33508"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis","datePublished":"2025-05-15T06:51:42+00:00","dateModified":"2025-05-15T06:51:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33508"},"wordCount":138,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33508#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1510.webp","keywords":["Boehringer Ingelheim","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33508#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33508","url":"https:\/\/flcube.com\/?p=33508","name":"Boehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33508#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33508#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1510.webp","datePublished":"2025-05-15T06:51:42+00:00","dateModified":"2025-05-15T06:51:43+00:00","description":"Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the filing for another indication approval of its investigational drug nerandomilast for the treatment of progressive pulmonary fibrosis (PPF). The preferential inhibitor of phosphodiesterase 4B (PDE4B) is also awaiting regulatory decisions from the NMPA for the treatment of idiopathic pulmonary fibrosis (IPF).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33508#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33508"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33508#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1510.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim's Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33508#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33508"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33508\/revisions"}],"predecessor-version":[{"id":33510,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33508\/revisions\/33510"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33509"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}